Transcode Therapeutics Stock Today
| RNAZ Stock | USD 0.34 0.04 9.71% |
Performance7 of 100
| Odds Of DistressOver 76
|
Transcode Therapeutics is trading at 0.3431 as of the 28th of November 2024; that is 9.71 percent decrease since the beginning of the trading day. The stock's open price was 0.38. Transcode Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Transcode Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of July 2021 | Category Healthcare | Classification Health Care |
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. The company was incorporated in 2016 and is based in Boston, Massachusetts. The company has 17.27 M outstanding shares of which 743.58 K shares are at this time shorted by private and institutional investors with about 0.5 trading days to cover. More on Transcode Therapeutics
Moving together with Transcode Stock
Moving against Transcode Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Transcode Stock Highlights
| CFO, CEO | Thomas MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTranscode Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Transcode Therapeutics' financial leverage. It provides some insight into what part of Transcode Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Transcode Therapeutics (RNAZ) is traded on NASDAQ Exchange in USA. It is located in 6 Liberty Square, Boston, MA, United States, 02109 and employs 10 people. Transcode Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.51 M. Transcode Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 17.27 M outstanding shares of which 743.58 K shares are at this time shorted by private and institutional investors with about 0.5 trading days to cover.
Transcode Therapeutics currently holds about 13.45 M in cash with (18.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Transcode Therapeutics Probability Of Bankruptcy
Ownership AllocationAbout 98.0 % of Transcode Therapeutics outstanding shares are held by general public with 0.009 (%) owned by insiders and only 1.99 % by institutional holders.
Check Transcode Ownership Details
Transcode Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Fmr Inc | 2024-09-30 | 175 | |
| Bank Of America Corp | 2024-06-30 | 55.0 | |
| First Personal Financial Services Inc | 2024-06-30 | 1.0 | |
| Financial Network Wealth Advisors Llc | 2024-09-30 | 0.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Sabby Management Llc | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-09-30 | 121.8 K | |
| Private Capital Management Llc | 2024-09-30 | 80.7 K | |
| Ubs Group Ag | 2024-06-30 | 74.9 K | |
| Sheets Smith Wealth Management | 2024-09-30 | 50.1 K |
Transcode Therapeutics Historical Income Statement
Transcode Stock Against Markets
Transcode Therapeutics Corporate Management
| RN MBA | Senior Operations | Profile | |
| Daniel MD | Chief Officer | Profile | |
| Anna Moore | Scientific CoFounder | Profile | |
| Calais Pharm | Executive Board | Profile | |
| Robert Dudley | CEO, CoFounder | Profile |
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.